Alimera Sciences Inc - ALIM Net earnings per one share for the last twelve months

Alimera Sciences Inc (ALIM) - corporate logo

The stable operation of certified implant production lines creates a reliable manufacturing foundation for Alimera Sciences (ALIM). The year-over-year EPS trend (TTM) illustrates this trajectory, where 0.20 indicates the current yield level. Growth is driven by the sales expansion of Iluvien and the deal with Endo, although strict regulatory oversight and the necessity to verify injection safety remain headwinds.

ALIM Alimera Sciences: Net earnings per share (EPS TTM) in the range 02/11/2024 - 02/20/2024

Alimera Sciences Inc - analytical breakdowns and key metrics (ALIM)

- issuer market value details:
Initial company analysis:Alimera Sciences
Flagship merchandise of Alimera Sciences, Inc.

This indicator reveals the gap between lagging accounting reports and real market growth rates. The metric captures the percentage change in trailing twelve-month earnings per share, assessing the efficiency of capital generation. Analyzing the historical annual dynamics of EPS TTM allows for a stress test of positions during a demand squeeze. For Alimera Sciences (ALIM), this trend reflects the commercial success of the Iluvien implant. Steady growth in this metric confirms the demand for long-term therapy for diabetic macular edema.

Competitor analysis for Alimera Sciences

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|Net earnings per share for the last 12 months KALA|IRD - Net earnings per share for the trailing year|Earnings per share for the last twelve months okyopharma.com (OKYO)|Net earnings per share (EPS TTM) Adverum Biotechnologies Inc. (ADVM)|Earnings per share for the last twelve months outlooktherapeutics.com OTLK|Net earnings per share for the last four quarters Clearside Biomedical, Inc. (CLSD)|NBY - Earnings per share for the last twelve months|Earnings per share for the trailing year KPRX (kiorapharma.com)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters